Anaesthetists’ drug dosing practices in class III obese surgical patients: A bi-national survey

Zahid Hussain, Karl Gadd, Colin Curtian, Corinne Mirkazmi, Gregory M. Peterson, Syed Tabish R Zaidi

Research output: Contribution to journalArticle

Abstract

Class III obese (body mass index ≥ 40 kg/m 2) patients, now regularly encountered clinically, have increased perioperative risks, including potentially from suboptimal drug dosing. However, current dosing guidelines are based on low-level evidence and may not be widely accepted. This study aimed to investigate anaesthetists’ dosing practices for class III obese surgical patients, explore if they had experienced an increased incidence of adverse events potentially related to drug dosing with these patients and assess which resources they consulted for dosing advice in this population. An electronic survey was emailed to 1000 randomly selected members of the Australian and New Zealand College of Anaesthetists. Data were summarised and the Pearson’s χ 2 test was used to compare respondents’ genders, geographic locations and seniority designations with the greater Australian and New Zealand College of Anaesthetists’ membership. There were 230 completed responses (response rate 23%). A large proportion (46%–76%) of respondents indicated they dose class III obese patients in keeping with current recommendations; however, substantial heterogeneity in dosing practices was found. Lean body weight was the most frequently used regimen for dosing propofol, non-depolarising muscle relaxants, sugammadex and opioids, whereas total body weight was most frequently used for suxamethonium. Nearly 70% of respondents reported using at least one resource to assist their dosing practices in obesity. Importantly, increased incidences of adverse events in class III obese patients related to drug dosing were commonly experienced by respondents. Until higher-level evidence is available for dosing class III obese patients, anaesthetists should consider current recommendations and exercise increased attention to dosing. Further clinician education may assist in optimising dosing in this patient group.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalAnaesthesia and Intensive Care
DOIs
Publication statusE-pub ahead of print - 21 Nov 2019

Fingerprint

Pharmaceutical Preparations
New Zealand
Neuromuscular Nondepolarizing Agents
Body Weight
Geographic Locations
Succinylcholine
Incidence
Propofol
Anesthetists
Surveys and Questionnaires
Opioid Analgesics
Body Mass Index
Obesity
Guidelines
Exercise
Education
Population

Cite this

Hussain, Zahid ; Gadd, Karl ; Curtian, Colin ; Mirkazmi, Corinne ; Peterson, Gregory M. ; R Zaidi, Syed Tabish. / Anaesthetists’ drug dosing practices in class III obese surgical patients: A bi-national survey. In: Anaesthesia and Intensive Care. 2019 ; pp. 1-6.
@article{a4a89bf496784b06860c0fef610db699,
title = "Anaesthetists’ drug dosing practices in class III obese surgical patients: A bi-national survey",
abstract = "Class III obese (body mass index ≥ 40 kg/m 2) patients, now regularly encountered clinically, have increased perioperative risks, including potentially from suboptimal drug dosing. However, current dosing guidelines are based on low-level evidence and may not be widely accepted. This study aimed to investigate anaesthetists’ dosing practices for class III obese surgical patients, explore if they had experienced an increased incidence of adverse events potentially related to drug dosing with these patients and assess which resources they consulted for dosing advice in this population. An electronic survey was emailed to 1000 randomly selected members of the Australian and New Zealand College of Anaesthetists. Data were summarised and the Pearson’s χ 2 test was used to compare respondents’ genders, geographic locations and seniority designations with the greater Australian and New Zealand College of Anaesthetists’ membership. There were 230 completed responses (response rate 23{\%}). A large proportion (46{\%}–76{\%}) of respondents indicated they dose class III obese patients in keeping with current recommendations; however, substantial heterogeneity in dosing practices was found. Lean body weight was the most frequently used regimen for dosing propofol, non-depolarising muscle relaxants, sugammadex and opioids, whereas total body weight was most frequently used for suxamethonium. Nearly 70{\%} of respondents reported using at least one resource to assist their dosing practices in obesity. Importantly, increased incidences of adverse events in class III obese patients related to drug dosing were commonly experienced by respondents. Until higher-level evidence is available for dosing class III obese patients, anaesthetists should consider current recommendations and exercise increased attention to dosing. Further clinician education may assist in optimising dosing in this patient group.",
keywords = "Anaesthetists, adverse events, class III obesity, dosing resources, drug dosing, survey",
author = "Zahid Hussain and Karl Gadd and Colin Curtian and Corinne Mirkazmi and Peterson, {Gregory M.} and {R Zaidi}, {Syed Tabish}",
year = "2019",
month = "11",
day = "21",
doi = "10.1177/0310057X19886596",
language = "English",
pages = "1--6",
journal = "Anaesthesia and Intensive Care",
issn = "0310-057X",
publisher = "Australian Society of Anaesthetists",

}

Anaesthetists’ drug dosing practices in class III obese surgical patients: A bi-national survey. / Hussain, Zahid; Gadd, Karl; Curtian, Colin; Mirkazmi, Corinne; Peterson, Gregory M. ; R Zaidi, Syed Tabish.

In: Anaesthesia and Intensive Care, 21.11.2019, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anaesthetists’ drug dosing practices in class III obese surgical patients: A bi-national survey

AU - Hussain, Zahid

AU - Gadd, Karl

AU - Curtian, Colin

AU - Mirkazmi, Corinne

AU - Peterson, Gregory M.

AU - R Zaidi, Syed Tabish

PY - 2019/11/21

Y1 - 2019/11/21

N2 - Class III obese (body mass index ≥ 40 kg/m 2) patients, now regularly encountered clinically, have increased perioperative risks, including potentially from suboptimal drug dosing. However, current dosing guidelines are based on low-level evidence and may not be widely accepted. This study aimed to investigate anaesthetists’ dosing practices for class III obese surgical patients, explore if they had experienced an increased incidence of adverse events potentially related to drug dosing with these patients and assess which resources they consulted for dosing advice in this population. An electronic survey was emailed to 1000 randomly selected members of the Australian and New Zealand College of Anaesthetists. Data were summarised and the Pearson’s χ 2 test was used to compare respondents’ genders, geographic locations and seniority designations with the greater Australian and New Zealand College of Anaesthetists’ membership. There were 230 completed responses (response rate 23%). A large proportion (46%–76%) of respondents indicated they dose class III obese patients in keeping with current recommendations; however, substantial heterogeneity in dosing practices was found. Lean body weight was the most frequently used regimen for dosing propofol, non-depolarising muscle relaxants, sugammadex and opioids, whereas total body weight was most frequently used for suxamethonium. Nearly 70% of respondents reported using at least one resource to assist their dosing practices in obesity. Importantly, increased incidences of adverse events in class III obese patients related to drug dosing were commonly experienced by respondents. Until higher-level evidence is available for dosing class III obese patients, anaesthetists should consider current recommendations and exercise increased attention to dosing. Further clinician education may assist in optimising dosing in this patient group.

AB - Class III obese (body mass index ≥ 40 kg/m 2) patients, now regularly encountered clinically, have increased perioperative risks, including potentially from suboptimal drug dosing. However, current dosing guidelines are based on low-level evidence and may not be widely accepted. This study aimed to investigate anaesthetists’ dosing practices for class III obese surgical patients, explore if they had experienced an increased incidence of adverse events potentially related to drug dosing with these patients and assess which resources they consulted for dosing advice in this population. An electronic survey was emailed to 1000 randomly selected members of the Australian and New Zealand College of Anaesthetists. Data were summarised and the Pearson’s χ 2 test was used to compare respondents’ genders, geographic locations and seniority designations with the greater Australian and New Zealand College of Anaesthetists’ membership. There were 230 completed responses (response rate 23%). A large proportion (46%–76%) of respondents indicated they dose class III obese patients in keeping with current recommendations; however, substantial heterogeneity in dosing practices was found. Lean body weight was the most frequently used regimen for dosing propofol, non-depolarising muscle relaxants, sugammadex and opioids, whereas total body weight was most frequently used for suxamethonium. Nearly 70% of respondents reported using at least one resource to assist their dosing practices in obesity. Importantly, increased incidences of adverse events in class III obese patients related to drug dosing were commonly experienced by respondents. Until higher-level evidence is available for dosing class III obese patients, anaesthetists should consider current recommendations and exercise increased attention to dosing. Further clinician education may assist in optimising dosing in this patient group.

KW - Anaesthetists

KW - adverse events

KW - class III obesity

KW - dosing resources

KW - drug dosing

KW - survey

UR - http://www.scopus.com/inward/record.url?scp=85075356140&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/anaesthetists-drug-dosing-practices-class-iii-obese-surgical-patients-binational-survey

U2 - 10.1177/0310057X19886596

DO - 10.1177/0310057X19886596

M3 - Article

SP - 1

EP - 6

JO - Anaesthesia and Intensive Care

JF - Anaesthesia and Intensive Care

SN - 0310-057X

ER -